Introduction
Rapidly growing markets for monoclonal antibodies (MAbs) have brought about the large-scale cultivation of hybridomas and the development of optimal processing schemes. The preliminary analysis needed for process design requires us to seek order of magnitudes of key rates, capacities, and other necessary data for orientation and identification of factors that need quantitative analysis. Herein we attempt to establish how basic biochemical and cellular determinants set the order of magnitude of the rate of monoclonal antibody production. Our order of magnitude estimate is consistent with experimental observations.
Dynamics of antibody synthesis
Antibody synthesis in hybridoma cells proceeds in a sequence of several well-known steps, shown in Fig. 1 . These steps are transcription, processing of the heteronuclear RNA (hnRN A), translation, assembly of polypeptides and their glycosylation, and secretion of the antibody. Antibody accounts for a large fraction of protein synthesized in Ab-producing cells. For instance, in rapidly growing MOPC 21 and MPC 11 myeloma cells, a single gene for each of the heavy (H) and light (L) chains may provide enough mRN A that leads to about 20-30% of the protein synthesized [1] .
We will now estimate the theoretical maximum rate of antibody synthesis, which is the steady state flux through the Ab production system.
1 These order of magnitude calculations will give an upper bound on the specific productivity of hybridoma cells, and are based on the cell's capacity for transcription and translation. 2 The maximum capacity for the other stages of Ab synthesis, such as glycosylation and secretion, are more difficult to evaluate at present. However, these steps would only serve to reduce our estimate of the maximum Ab synthesis rate, ifthey would prove to be capacity limiting. As will be shown below, the estimate based on the processes of transcription and translation agrees with experimental data.
A dynamic mass balance on the cytoplasmic Ab mRN A concentration is: Assuming that in balanced growth, the amount of mRN A per cell is in a quasi-steady state, we obtain
Such an estimate should not be confused with the characteristic response times associated with the individual steps in the process. For example, the response time, defined as the approximate length of time for the process to occur, is 20-150 min for the glycosylation/secretion step [2, 3] , and 40 min for nuclear processing [4] . Although these may be the steps in the Ab synthesis pathway with the slowest response times, they do not necessarily limit the cell's capacity for Ab synthesis. 2 Similar calculations have been used to estima te the rate of zymogen synthesis in cocoonase zymogen cells [5] . The various parameters appearing in this expression may be estimated from the available literature. Reported values for v c are 83 nucleotides/s for HeLa ribosomal RNA [6] , 67 in poliovirus [7] , and 45 in E. coli [8] . The reported values for s e are 75 nucleotides/polymerase in E. coli [9] , and 79-92 in Triturus viridescens [10) . Based on the physical size of the polymerase II molecule, the minimum spacing is about 38 nucleotides [10] , although it is unlikely that this spacing can be physically achieved. Approximately 70-90% of the hn-RN A produced in the nucleus is transported to the cytoplasm [11] , so E falls in the range of 0.7-0.9. The average half-life of Ab mRN A has been measured to be 12 h [12] , corresponding to a k value of 1.61 · 10-5 s - The reported estimates of 54,000 LmRNA/cell [11] , and 40,000 LmRNA and 30,000 H mRNA [13] fall within this range. The upper limit for the [mRNA] ss can be extended to 122,000 mRN A molecules/cell if the minimum polymerase spacing of 38 nucleotides/polymerase is used.
The equation for translation of Ab mRN A, assuming that translation is a first order process [14] , is:
We assume that the ribosome concentration is not limiting and, therefore, the translation rate is independent of ribosome concentration. Reported values for the ribosome velocity, v s , are 20 nucleotides/s in myeloma [1] , 25 in reticulocytes [15] , and 48-60 in Salmonella typhinurium [16] . The number of nucleotides between ribosomes, S 8 , is reported to be 90-100 in myeloma [1] and reticulocytes [15] , and 88-99 in somatotropes and mammotropes [17] . The factor of 0.5 occurs because two H and two L polypeptide chains are needed for the assembly of one complete Ab molecule. To estimate the maximum Ab production rate, we have neglected the turnover of either the H or L chains. The H chains are believed to be relatively stable, whîle the L chains can exhibit significant turnover -L chains are reported to be produced in excess of H chains [3] . The rate of H chain synthesis thus forms a suitable upper bound on the MAb excretion rate. The range of the maximum Ab synthesis rate can then be calculated using Eq. (3) Therefore, based on the physical constraints enumerated above (the observed polymerase and ribosome packing density, and transcription and translation velocities), the theoretical maximum output of antibody from a myeloma cell is on the order of 2300-8000 Ab molecules/cell/s. If the maximum estimated value of 122,000 mRNA/cell is used, the upper limit for the Ab production rate becomes 17,000 Ab molecules/cell/s.
Discussion
The reported values of MAb production range from 17 to 8000 Ab/cell/s for various hybridoma cell lines (Table 1) , with most values falling in the range of 500-3000. Our estimate of the maximum rate seems, therefore, reasonable. Fig. 2 shows the normalized MAb concentration plotted against the time integral of the viable cell concentration, for several sets ofbatch data reported in the literature. The slope of this curve, which gives the specific productivity, is nearly linear up to the point around 10
8 cells · h/cm 3 for all the data used. At this point, one or more critical components seem to be depleted from the standard media, causing the MAb production to decline [18] . It has been shown that when the essential amino acids were added to the media at this point, the cells continued to synthesize antibody at the same rate [18] . Figure 2 indicates that the specific productivity of MAb is nearly constant at the individual cell line's characteristic rate, as long as the necessary nutrients are available. All these data sets corne from experiments with 5-10% serum in the media. Data from our laboratory show that the specific MAb production rate is serum independent [19] , except under long term adaptation to very low serum levels (unpublished results).
The high MAb-producing hybridoma cell lines, shown in Table 1 , secrete MAb at rates that are close to our estimated capacity of the epigenic system. If nutritional conditions are not limiting, improvements in the specific MAb production rate will not be achieved through improved processing technology but rather through modification of cellular components. At present it is uncertain how successfully we can manipulate the cell's protein synthesis machinery. Our results, therefore, support the view that economically successful large-scale cultivation of hybridomas is likely to depend primarily on the selection of: 1) a high producer, and 2) a processing scheme that supports high cell densities .
